All In Biotech

Drug Trial Radar · NCT05584111

Oral Administration of STC-15 in Subjects With Advanced Malignancies

Phase 1 Study to Evaluate the Safety, PK, PD, and Clinical Activity of STC-15, a METTL-3 Inhibitor, in Subjects With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

42

Actual

Start

Nov 15, 2022

Primary completion

Aug 30, 2024

Study completion Dec 22, 2024

Sponsor

Lead sponsor
STORM Therapeutics LTDIndustry
Sponsor type
Industry
First posted
Oct 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm. The study is designed to systematically assess safety and tolerability, pharmacokinetics, pharmacodynamics and clinical activity of STC-15 in adult subjects with advanced malignancies. Dose levels for further evaluation in expansion cohorts will be selected based on all available PK, pharmacodynamic, target engagement, efficacy, safety, and tolerability data including long-term safety data beyond dose limiting toxicities (DLTs). The study may be amended to evaluate STC-15 in combination with a Food and Drug Administration-approved standard of care treatment regimen, which could encompass targeted/chemotherapy, radiation therapy and/or immunotherapy with immune checkpoint blockers.

Conditions

  • Advanced Cancer
  • Advanced Solid Tumor
  • Cancer

Interventions

  • STC-15Drug

    STC-15 oral capsules various dosing regimen in 3-week cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Related Treatment Emergent Adverse EventsTime frame: Screening through end of treatment, approximately 6 months
  2. Cmax (PK)Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose on Cycle 1 Day 1 (C1D1)
  3. Tmax (PK)Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose on C1D1
  4. Ctrough (PK)Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours Pre-dose on Cycle 2 Day 1
  5. Terminal Elimination Half Life (PK)Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours post dose on C1D1
  6. AUC (PK)Time frame: For daily administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours on C1D1; for MWF administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours on C1D1.
  7. Average Concentration (PK)Time frame: For daily administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours on C1D1; for MWF administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours on C2D1.
  8. Systemic Clearance (PK)Time frame: For daily administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours on C1D1; for MWF administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours on C1D1.
  9. Volume of Distribution at Steady-state (PK)Time frame: For daily administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours on C1D1; for MWF administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours on C1D1.
  10. Accumulation Ratio From First Dose to Steady-state (PK)Time frame: For MWF administration: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 48 hours on C1D1 and C2D1.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Honor Health

    Scottsdale, Arizona

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.